Drug Prices
In a study reported this week in JAMA Network Open, researchers found no association between a drug’s list price and research and development costs. The study looked at 60 drugs approved by the Food and Drug Administration between 2009 and 2018.
AHA comments to MedPAC regarding topics to be discussed at the commissioner’s September meeting.
Morgan Health, JPMorgan Chase’s health care venture arm, has been busy making good on its pledge to invest $250 million in health care startups to help reshape health care. The company recently invested $20 million in LetsGetChecked, which offers at-home diagnostic and genetic testing, virtual…
America’s hospitals and health systems continue to deal with the difficult challenges of high inflation and ongoing effects of the COVID-19 pandemic. Specifically, hospitals are facing significant increases in costs of labor from workforce shortages, drugs, equipment and supplies (including food…
The Senate yesterday voted 51-50 to approve the Inflation Reduction Act of 2022 (H.R. 5376), a roughly $700 billion social spending package that includes health care, climate change and tax provisions.
The Consumer Price Index has had the fastest increase in over 40 years, the Bureau of Labor Statistics reported today.
Launch prices for new brand-name prescription drugs increased 20% per year between 2008 and 2021, according to a study reported yesterday in JAMA.
A new AHA report highlights the significant growth in expenses across labor, drugs, and supplies, as well as the impact that rising inflation is having on hospital prices.
In a statement submitted to the Senate Finance Committee for a hearing on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies.
AHA shares proposals to lower Medicare drug prices with congress.